Bernstein lowered the firm’s price target on Alnylam Pharmaceuticals to $218 from $237 and keeps an Outperform rating on the shares after the FDA issued a complete response letter rejecting the label expansion of Onpattro in ATTR-CM. The firm lowered the price target based on slightly lower commercial expectations for Alnylam’s ATTR franchise, but continues to like the setup heading into HELIOS-B data next year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY:
- Alnylam price target lowered to $210 from $252 at Evercore ISI
- Alnylam price target lowered to $260 from $265 at TD Cowen
- Alnylam price target lowered to $234 from $250 at BMO Capital
- BridgeBio has positive readthrough from Alnylam’s CRL, says BofA
- Alnylam price target lowered to $233 from $266 at Citi